{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"92"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"254"},{"groupId":"OG001","value":"235"}]}],"title":"Other Non-SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"220"}]}],"title":"Died"}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"276"}],"units":"Participants"}],"description":"The number of participants with serious AEs (SAEs), other non-serious AEs and participants who died. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"NUMBER","populationDescription":"Participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (up to 37 months)","title":"Number of Participants With Adverse Events (AEs) and the Number of Participants Who Died","type":"SECONDARY","unitOfMeasure":"participants"}